Guosheng Securities gives Huisheng Bio a buy rating: weak demand + cost pressure dragging down performance is expected to gradually improve since Q2 – yqqlm

Post date April 24, 2022 — 12:43 Post Lock

Key Data Concepts:
? These are the company names, stock quotes, topics, and entities related to this data.

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Related Data

Kangtai Medical: The company's decline in sales of blood oxygen products in 2021 is mainly affected by changes in demand and the high base of the previous year

May 20, 2022 — 17:56

Huichuangda: In 2021, the company will strengthen the research and development of automated production lines, further improve the degree of automation of production lines, enhance production efficiency, and realize automated production of various processes

May 20, 2022 — 17:55

The secretary of the board of CTI Testing replied: The company hopes to make a modest contribution to the fight against the epidemic – yqqlm

May 20, 2022 — 17:55

Xiling Power: The sales revenue of some of the company's auto segment customers was affected, but the company's main customers Toyota and BYD were less affected

May 20, 2022 — 17:50

Jinlei shares: the company has been in a state of full production in the first quarter and April, and the capacity utilization rate is close to saturation

May 20, 2022 — 17:49

Desheng Technology: 002908 Desheng Technology Performance Briefing Session, Roadshow Activity Information 20220520- CFi.CN Zhongcai Network

May 20, 2022 — 17:46

"Warmly welcome the new president!" China Merchants Bank's stock price rebounded 13%, and its market value returned to the trillion-dollar club.

May 20, 2022 — 17:45

"Warmly welcome the new president!" China Merchants Bank's share price rebounded 13%, and its market value returned to the trillion-dollar club.

May 20, 2022 — 17:45

The dividend of the epidemic subsided, and the stable medical 752 million cross-border injection and puncture track-News Channel-Hexun.com

May 20, 2022 — 17:40

Home » News » Guosheng Securities gives Huisheng Bio a buy rating: weak demand + cost pressure dragging down performance is expected to gradually improve since Q2 – yqqlm